Login Register Cart 0
Review Article

CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy

Author(s): Yang-Hong Ni, Xia Zhao* and Wei Wang*

Volume 20, Issue 2, 2020

Page: [109 - 126] Pages: 18

DOI: 10.2174/1566523220666200623170738

Price: $65

Abstract

CD24, is a mucin-like GPI-anchored molecules. By immunohistochemistry, it is widely detected in many solid tumors, such as breast cancers, genital system cancers, digestive system cancers, neural system cancers and so on. The functional roles of CD24 are either fulfilled by combination with ligands or participate in signal transduction, which mediate the initiation and progression of neoplasms. However, the character of CD24 remains to be intriguing because there are still opposite voices about the impact of CD24 on tumors. In preclinical studies, CD24 target therapies, including monoclonal antibodies, target silencing by RNA interference and immunotherapy, have shown us brighten futures on the anti-tumor application. Nevertheless, evidences based on clinical studies are urgently needed. Here, with expectancy to spark new ideas, we summarize the relevant studies about CD24 from a tumor perspective.

Keywords: CD24, cancer, mAb, immunotherapy, lymphocytes, granulocytes.

« Previous Next »
[1]
Springer T, Galfrè G, Secher DS, Milstein C. Monoclonal xenogeneic antibodies to murine cell surface antigens: identification of novel leukocyte differentiation antigens. Eur J Immunol 1978; 8(8): 539-51.
[http://dx.doi.org/10.1002/eji.1830080802] [PMID: 81133]
[2]
Abramson CS, Kersey JH, LeBien TW. A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage. J Immunol 1981; 126(1): 83-8.
[3]
Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990; 144(2): 638-41.
[4]
Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol 2010; 7(2): 100-3.
[http://dx.doi.org/10.1038/cmi.2009.119] [PMID: 20154703]
[5]
Pirruccello SJ, LeBien TW. The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986; 136(10): 3779-84.
[6]
Kay R, Takei F, Humphries RK. Expression cloning of a cDNA encoding M1/69-J11d heat-stable antigens. J Immunol 1990; 145(6): 1952-9.
[7]
Kay R, Rosten PM, Humphries RK. CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol 1991; 147(4): 1412-6.
[8]
Zarn JA, Jackson DG, Bell MV, et al. The small cell lung cancer antigen cluster-4 and the leukocyte antigen CD24 are allelic isoforms of the same gene (CD24) on chromosome band 6q21. Cytogenet Cell Genet 1995; 70(1-2): 119-25.
[http://dx.doi.org/10.1159/000134075] [PMID: 7736776]
[9]
Hough MR, Rosten PM, Sexton TL, Kay R, Humphries RK. Mapping of CD24 and homologous sequences to multiple chromosomal loci. Genomics 1994; 22(1): 154-61.
[http://dx.doi.org/10.1006/geno.1994.1356] [PMID: 7959762]
[10]
Wenger RH, Rochelle JM, Seldin MF, Köhler G, Nielsen PJ. The heat stable antigen (mouse CD24) gene is differentially regulated but has a housekeeping promoter. J Biol Chem 1993; 268(31): 23345-52.
[PMID: 8226859]
[11]
Tan Y, Zhao M, Xiang B, Chang C, Lu Q. CD24: from a hematopoietic differentiation antigen to a genetic risk factor for multiple autoimmune diseases. Clin Rev Allergy Immunol 2016; 50(1): 70-83.
[http://dx.doi.org/10.1007/s12016-015-8470-2] [PMID: 25666875]
[12]
Shamai S, Nabiochtchikov I, Kraus S, et al. CD24 and APC genetic polymorphisms in pancreatic cancers as potential biomarkers for clinical outcome. PLoS One 2015; 10(9) e0134469
[http://dx.doi.org/10.1371/journal.pone.0134469] [PMID: 26394139]
[13]
Zhang Y, Li B, Zhang X, et al. CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 2017; 56(2): 641-50.
[http://dx.doi.org/10.1002/mc.22522] [PMID: 27377469]
[14]
Wang L, Lin S, Rammohan KW, et al. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet 2007; 3(4) e49
[http://dx.doi.org/10.1371/journal.pgen.0030049] [PMID: 17411341]
[15]
Buck K, Hug S, Seibold P, et al. CD24 polymorphisms in breast cancer: impact on prognosis and risk. Breast Cancer Res Treat 2013; 137(3): 927-37.
[http://dx.doi.org/10.1007/s10549-012-2325-9] [PMID: 23314606]
[16]
Sadot E, Kraus S, Stein M, et al. CD24 gene polymorphism--a novel prognostic factor in esophageal cancer. Int J Biol Markers 2014; 29(1): e49-54.
[http://dx.doi.org/10.5301/jbm.5000071] [PMID: 24474454]
[17]
Li D, Zheng L, Jin L, et al. CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection. Hepatology 2009; 50(3): 735-42.
[http://dx.doi.org/10.1002/hep.23047] [PMID: 19610054]
[18]
Jia ZF, Wang LZ, Cao XY, et al. CD24 genetic variants contribute to overall survival in patients with gastric cancer. World J Gastroenterol 2016; 22(7): 2373-82.
[http://dx.doi.org/10.3748/wjg.v22.i7.2373] [PMID: 26900300]
[19]
Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001; 166(9): 5567-77.
[20]
Elghetany MT, Patel J. Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development. Am J Hematol 2002; 71(4): 348-9.
[http://dx.doi.org/10.1002/ajh.10176] [PMID: 12447971]
[21]
Li O, Zheng P, Liu Y. CD24 expression on T cells is required for optimal T cell proliferation in lymphopenic host. J Exp Med 2004; 200(8): 1083-9.
[http://dx.doi.org/10.1084/jem.20040779] [PMID: 15477346]
[22]
Williams LA, McLellan AD, Summers KL, Sorg RV, Fearnley DB, Hart DN. Identification of a novel dendritic cell surface antigen defined by carbohydrate specific CD24 antibody cross-reactivity. Immunology 1996; 89(1): 120-5.
[http://dx.doi.org/10.1046/j.1365-2567.1996.d01-720.x] [PMID: 8911149]
[23]
De Bruijn ML, Peterson PA, Jackson MR. Induction of heat-stable antigen expression by phagocytosis is involved in in vitro activation of unprimed CTL by macrophages. J Immunol 1996; 156(8): 2686-92.
[24]
Shewan D, Calaora V, Nielsen P, Cohen J, Rougon G, Moreau H. mCD24, a glycoprotein transiently expressed by neurons, is an inhibitor of neurite outgrowth. J Neurosci 1996; 16(8): 2624-34.
[http://dx.doi.org/10.1523/JNEUROSCI.16-08-02624.1996] [PMID: 8786438]
[25]
Magnaldo T, Barrandon Y. CD24 (heat stable antigen, nectadrin), a novel keratinocyte differentiation marker, is preferentially expressed in areas of the hair follicle containing the colony-forming cells. J Cell Sci 1996; 109(Pt 13): 3035-45.
[PMID: 9004038]
[26]
Figarella-Branger D, Moreau H, Pellissier JF, Bianco N, Rougon G. CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle. Acta Neuropathol 1993; 86(3): 275-84.
[http://dx.doi.org/10.1007/BF00304142] [PMID: 8213086]
[27]
Enk AH, Katz SI. Heat-stable antigen is an important costimulatory molecule on epidermal Langerhans’ cells. J Immunol 1994; 152(7): 3264-70.
[28]
Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 2006; 8(1): R7.
[http://dx.doi.org/10.1186/bcr1371] [PMID: 16417656]
[29]
Chen CY, Kimura H, Landek-Salgado MA, et al. Regenerative potentials of the murine thyroid in experimental autoimmune thyroiditis: role of CD24. Endocrinology 2009; 150(1): 492-9.
[http://dx.doi.org/10.1210/en.2008-0639] [PMID: 18801910]
[30]
Zhou Q, Rammohan K, Lin S, et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci USA 2003; 100(25): 15041-6.
[http://dx.doi.org/10.1073/pnas.2533866100] [PMID: 14657362]
[31]
Ahmed MA, Jackson D, Seth R, et al. CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation. Inflamm Bowel Dis 2010; 16(5): 795-803.
[http://dx.doi.org/10.1002/ibd.21134] [PMID: 19998456]
[32]
Fogel M, Friederichs J, Zeller Y, et al. CD24 is a marker for human breast carcinoma. Cancer Lett 1999; 143(1): 87-94.
[http://dx.doi.org/10.1016/S0304-3835(99)00195-0] [PMID: 10465342]
[33]
Kwon MJ, Han J, Seo JH, et al. CD24 overexpression is associated with poor prognosis in luminal a and triple-negative breast cancer. PLoS One 2015; 10(10) e0139112
[http://dx.doi.org/10.1371/journal.pone.0139112] [PMID: 26444008]
[34]
Jang MH, Kang HJ, Jang KS, Paik SS, Kim WS. Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer. Oncol Lett 2016; 12(4): 2728-33.
[http://dx.doi.org/10.3892/ol.2016.4987] [PMID: 27698848]
[35]
Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003; 9(13): 4906-13.
[PMID: 14581365]
[36]
Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou AM, Tsipis A, Patsouris E. CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract 2009; 205(8): 524-33.
[http://dx.doi.org/10.1016/j.prp.2009.01.008] [PMID: 19243896]
[37]
Zheng Z, Shao N, Weng H, et al. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma. Med Oncol 2015; 32(1): 275.
[http://dx.doi.org/10.1007/s12032-014-0275-2] [PMID: 25429827]
[38]
Moon YW, An HJ, Koo JS, et al. CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator. Oncotarget 2017; 9(2): 2622-30.
[http://dx.doi.org/10.18632/oncotarget.23519] [PMID: 29416796]
[39]
Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 2006; 202(8): 569-76.
[http://dx.doi.org/10.1016/j.prp.2006.05.004] [PMID: 16828238]
[40]
Simonetti S, Terracciano L, Zlobec I, et al. Immunophenotyping analysis in invasive micropapillary carcinoma of the breast: role of CD24 and CD44 isoforms expression. Breast 2012; 21(2): 165-70.
[http://dx.doi.org/10.1016/j.breast.2011.09.004] [PMID: 22014860]
[41]
Tramm T, Kim JY, Leibl S, Moinfar F, Tavassoli FA. Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast. Int J Pathol 2016; 469(3): 285-95.
[http://dx.doi.org/10.1007/s00428-016-1966-1] [PMID: 27287269]
[42]
Chen Y, Song J, Jiang Y, Yu C, Ma Z. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma. Int J Clin Exp Pathol 2015; 8(9): 11287-95.
[PMID: 26617852]
[43]
Bernardi MA, Logullo AF, Pasini FS, et al. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. Oncol Rep 2012; 27(1): 28-38.
[PMID: 21956537]
[44]
Kim HJ, Kim MJ, Ahn SH, et al. Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 2011; 20(1): 78-85.
[http://dx.doi.org/10.1016/j.breast.2010.08.001] [PMID: 20810282]
[45]
Surowiak P, Materna V, Paluchowski P, et al. CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res 2006; 26(1B): 629-34.
[PMID: 16739331]
[46]
Wang Z, Shi Q, Wang Z, et al. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 2011; 207(8): 505-13.
[http://dx.doi.org/10.1016/j.prp.2011.06.009] [PMID: 21802218]
[47]
Cong F, Yu H, Gao X. Expression of CD24 and B7-H3 in breast cancer and the clinical significance. Oncol Lett 2017; 14(6): 7185-90.
[http://dx.doi.org/10.3892/ol.2017.7142] [PMID: 29344150]
[48]
Kim HJ, Kim JB, Lee KM, et al. Isolation of CD24(high) and CD24(low/-) cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7. Cancer Lett 2007; 258(1): 98-108.
[http://dx.doi.org/10.1016/j.canlet.2007.08.025] [PMID: 17950993]
[49]
Rostoker R, Abelson S, Genkin I, et al. CD24(+) cells fuel rapid tumor growth and display high metastatic capacity. Breast Cancer Res 2015; 17: 78.
[http://dx.doi.org/10.1186/s13058-015-0589-9] [PMID: 26040280]
[50]
Kristiansen G, Machado E, Bretz N, et al. Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Lab Invest 2010; 90(7): 1102-16.
[http://dx.doi.org/10.1038/labinvest.2010.70] [PMID: 20351695]
[51]
Jing X, Cui X, Liang H, et al. CD24 is a potential biomarker for prognosis in human breast carcinoma. Cell Physiol Biochem 2018; 48(1): 111-9.
[http://dx.doi.org/10.1159/000491667]
[52]
Zhang P, Zheng P, Liu Y. Amplification of the CD24 gene is an independent predictor for poor prognosis of breast cancer. Front Genet 2019; 10: 560.
[http://dx.doi.org/10.3389/fgene.2019.00560] [PMID: 31244889]
[53]
Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001; 98(3): 1176-81.
[http://dx.doi.org/10.1073/pnas.98.3.1176] [PMID: 11158614]
[54]
Kristiansen G, Denkert C, Schlüns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002; 161(4): 1215-21.
[http://dx.doi.org/10.1016/S0002-9440(10)64398-2] [PMID: 12368195]
[55]
Choi YL, Kim SH, Shin YK, et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol 2005; 97(2): 379-86.
[http://dx.doi.org/10.1016/j.ygyno.2005.01.018] [PMID: 15863133]
[56]
Moulla A, Miliaras D, Sioga A, Kaidoglou A, Economou L. The immunohistochemical expression of CD24 and CD171 adhesion molecules in borderline ovarian tumors. Pol J Pathol 2013; 64(3): 180-4.
[http://dx.doi.org/10.5114/pjp.2013.38135]
[57]
Soltész B, Lukács J, Szilágyi E, et al. Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients. J Biotechnol 2019; 298: 16-20.
[http://dx.doi.org/10.1016/j.jbiotec.2019.03.018] [PMID: 30959137]
[58]
Nakamura K, Terai Y, Tanabe A, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol Rep 2017; 37(6): 3189-200.
[http://dx.doi.org/10.3892/or.2017.5583] [PMID: 28440503]
[59]
Zeng C, Chen T, Zhang Y, Chen Q. Hedgehog signaling pathway regulates ovarian cancer invasion and migration via adhesion molecule CD24. J Cancer 2017; 8(5): 786-92.
[http://dx.doi.org/10.7150/jca.17712] [PMID: 28382140]
[60]
Surowiak P, Materna V, Kaplenko I, et al. Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue. Int J Gynecol Cancer 2006; 16(2): 515-21.
[http://dx.doi.org/10.1111/j.1525-1438.2006.00555.x]
[61]
Runz S, Keller S, Rupp C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol 2007; 107(3): 563-71.
[http://dx.doi.org/10.1016/j.ygyno.2007.08.064] [PMID: 17900673]
[62]
Davidson B. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. Hum Pathol 2016; 58: 123-7.
[http://dx.doi.org/10.1016/j.humpath.2016.08.005] [PMID: 27589896]
[63]
Schreiber L, Raanan C, Amsterdam A. CD24 and Nanog identify stem cells signature of ovarian epithelium and cysts that may develop to ovarian cancer. Acta Histochem 2014; 116(2): 399-406.
[http://dx.doi.org/10.1016/j.acthis.2013.09.007] [PMID: 24103524]
[64]
Wang G, Zhang Z, Ren Y. TROP-1/Ep-CAM and CD24 are potential candidates for ovarian cancer therapy. Int J Clin Exp Pathol 2015; 8(5): 4705-14.
[PMID: 26191160]
[65]
Kwon GY, Ha H, Ahn G, Park SY, Huh SJ, Park W. Role of CD24 protein in predicting metastatic potential of uterine cervical squamous cell carcinoma in patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69(4): 1150-6.
[http://dx.doi.org/10.1016/j.ijrobp.2007.04.071] [PMID: 17692475]
[66]
Sung CO, Park W, Choi Y-L, et al. Prognostic significance of CD24 protein expression in patients treated with adjuvant radiotherapy after radical hysterectomy for cervical squamous cell carcinoma. Radiother Oncol 2010; 95(3): 359-64.
[http://dx.doi.org/10.1016/j.radonc.2010.01.007] [PMID: 20153907]
[67]
Tanaka T, Terai Y, Kogata Y, et al. CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer. Oncol Rep 2015; 34(5): 2282-8.
[http://dx.doi.org/10.3892/or.2015.4257] [PMID: 26351781]
[68]
Pei Z, Zhu G, Huo X, et al. CD24 promotes the proliferation and inhibits the apoptosis of cervical cancer cells in vitro. Oncol Rep 2016; 35(3): 1593-601.
[http://dx.doi.org/10.3892/or.2015.4521] [PMID: 26707501]
[69]
Karahan N, Güney M, Oral B, Kapucuoglu N, Mungan T. CD24 expression is a poor prognostic marker in endometrial carcinoma. Eur J Gynaecol Oncol 2006; 27(5): 500-4.
[PMID: 17139987]
[70]
Kim KH, Choi JS, Kim JM, et al. Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histol Histopathol 2009; 24(3): 309-16.
[PMID: 19130400]
[71]
Ono YJ, Tanabe A, Tanaka T, et al. Met signaling cascade is amplified by the recruitment of phosphorylated met to lipid rafts via CD24 and leads to drug resistance in endometrial cancer cell lines. Mol Cancer Ther 2015; 14(10): 2353-63.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0187] [PMID: 26227486]
[72]
Dong J-P, Dai Z-H, Jiang Z-X, et al. CD24: a marker of granulosa cell subpopulation and a mediator of ovulation. Cell Death Dis 2019; 10(11): 791-1.
[http://dx.doi.org/10.1038/s41419-019-1995-1] [PMID: 31624236]
[73]
Sano A, Kato H, Sakurai S, et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 2009; 16(2): 506-14.
[http://dx.doi.org/10.1245/s10434-008-0252-0] [PMID: 19050962]
[74]
Darwish NS, Kim MA, Chang MS, et al. Prognostic significance of CD24 expression in gastric carcinoma. Cancer Res Treat 2004; 36(5): 298-302.
[http://dx.doi.org/10.4143/crt.2004.36.5.298]
[75]
Bektas S, Bahadir B, Ucan BH, Ozdamar SO. CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance. Pathol Oncol Res 2010; 16(4): 569-77.
[http://dx.doi.org/10.1007/s12253-010-9248-8] [PMID: 20177845]
[76]
Fujikuni N, Yamamoto H, Tanabe K, et al. Hypoxia-mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion. Cancer Sci 2014; 105(11): 1411-20.
[http://dx.doi.org/10.1111/cas.12522] [PMID: 25174257]
[77]
Liu X, Yu H, Cai H, Wang Y. Expression of CD24, p21, p53, and c-myc in alpha-fetoprotein-producing gastric cancer: Correlation with clinicopathologic characteristics and survival. J Surg Oncol 2014; 109(8): 859-64.
[http://dx.doi.org/10.1002/jso.23599] [PMID: 24619835]
[78]
Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee CW, Lee CC. CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis. BMC Gastroenterol 2012; 12: 95.
[http://dx.doi.org/10.1186/1471-230X-12-95] [PMID: 22839505]
[79]
Wang YC, Wang JL, Kong X, et al. CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation. Apoptosis 2014; 19(4): 643-56.
[http://dx.doi.org/10.1007/s10495-013-0949-9]
[80]
Chou Y-Y, Jeng Y-M, Lee T-T, et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 2007; 14(10): 2748-58.
[http://dx.doi.org/10.1245/s10434-007-9501-x] [PMID: 17680316]
[81]
Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005; 11(18): 6574-81.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0606]
[82]
Sagiv E, Memeo L, Karin A, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006; 131(2): 630-9.
[http://dx.doi.org/10.1053/j.gastro.2006.04.028] [PMID: 16890615]
[83]
Ahmed MAH, Al-Attar A, Kim J, et al. CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer. J Clin Pathol 2009; 62(12): 1117-22.
[http://dx.doi.org/10.1136/jcp.2009.069310] [PMID: 19946098]
[84]
Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009; 15(18): 2258-64.
[http://dx.doi.org/10.3748/wjg.15.2258] [PMID: 19437567]
[85]
Wang W, Wang X, Peng L, et al. CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci 2010; 101(1): 112-9.
[http://dx.doi.org/10.1111/j.1349-7006.2009.01370.x] [PMID: 19860845]
[86]
Kraus S, Shapira S, Kazanov D, et al. Predictive levels of CD24 in peripheral blood leukocytes for the early detection of colorectal adenomas and adenocarcinomas. Dis Markers 2015; 2015, 916098
[http://dx.doi.org/10.1155/2015/916098] [PMID: 26078485]
[87]
Miller E, Shapira S, Gur E, et al. Increased expression of CD24 in nonmelanoma skin cancer. Int J Biol Markers 2012; 27(4): e331-6.
[http://dx.doi.org/10.5301/JBM.2012.9935] [PMID: 23250778]
[88]
Jackson D, Waibel R, Weber E, Bell J, Stahel RA. CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 1992; 52(19): 5264-70.
[PMID: 1327504]
[89]
Pass MK, Quintini G, Zarn JA, Zimmermann SM, Sigrist JA, Stahel RA. The 5′-flanking region of human CD24 gene has cell-type-specific promoter activity in small-cell lung cancer. Int J Cancer 1998; 78(4): 496-502.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19981109)78:4<496:AID-IJC17>3.0.CO;2-4] [PMID: 9797140]
[90]
Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003; 88(2): 231-6.
[http://dx.doi.org/10.1038/sj.bjc.6600702] [PMID: 12610508]
[91]
Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol 2010; 5(5): 649-57.
[http://dx.doi.org/10.1097/JTO.0b013e3181d5e554] [PMID: 20354454]
[92]
Pinato DJ, Nya P, Sharma R, Mauri FA. CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma. J Clin Pathol 2013; 66(3): 256-9.
[http://dx.doi.org/10.1136/jclinpath-2012-201020] [PMID: 23087328]
[93]
Majores M, Schindler A, Fuchs A, et al. Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients. BMC Clin Pathol 2015; 15: 19.
[http://dx.doi.org/10.1186/s12907-015-0019-z] [PMID: 26578846]
[94]
Liu D-H, An M, Bao B-L, Ren F, Xia P. Nicotine inhibits CD24 expression in Lewis lung carcinoma cells by upregulation of RAS expression. Int J Oncol 2018; 53(2): 815-22.
[http://dx.doi.org/10.3892/ijo.2018.4415] [PMID: 29845249]
[95]
Yang XR, Xu Y, Yu B, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 2009; 15(17): 5518-27.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-0151]
[96]
Liu B, Zhang Y, Liao M, et al. Clinicopathologic and prognostic significance of CD24 in gallbladder carcinoma. Pathol Oncol Res 2011; 17(1): 45-50.
[http://dx.doi.org/10.1007/s12253-010-9278-2] [PMID: 20567952]
[97]
Su MC, Hsu C, Kao HL, Jeng YM. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 2006; 235(1): 34-9.
[http://dx.doi.org/10.1016/j.canlet.2005.03.059] [PMID: 16125303]
[98]
Agrawal S, Kuvshinoff BW, Khoury T, et al. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg 2007; 11(4): 445-51.
[http://dx.doi.org/10.1007/s11605-007-0091-5] [PMID: 17436128]
[99]
Keeratichamroen S, Leelawat K, Thongtawee T, et al. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. Int J Oncol 2011; 39(4): 873-81.
[PMID: 21687942]
[100]
Kim K, Min HS, Chie EK, et al. CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. World J Gastroenterol 2013; 19(9): 1438-43.
[http://dx.doi.org/10.3748/wjg.v19.i9.1438] [PMID: 23539485]
[101]
Maimaitiming A, Zhou X, Ma X, et al. Clinicopathological and Prognostic Value of Plasma CD24 Level in Hepatocellular Carcinoma. J Invest Surg 2018; 33(6): 536-41.
[http://dx.doi.org/10.1080/08941939.2018.1535009]
[102]
Liu B, Yang Y, Han S, Zhang L, Bai Y, Fang X. Plasma CD24 as a novel useful biomarker in differentiating hepatocellular carcinoma patients from normal individuals. Hepatogastroenterology 2013; 60(126): 1245-50.
[PMID: 23321030]
[103]
Jacob J, Bellach J, Grutzmann R, et al. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 2004; 4(5): 454-60.
[http://dx.doi.org/10.1159/000079824]
[104]
Ikenaga N, Ohuchida K, Mizumoto K, et al. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas. Hum Pathol 2010; 41(10): 1466-74.
[http://dx.doi.org/10.1016/j.humpath.2010.04.004] [PMID: 20619441]
[105]
Zhu J, He J, Liu Y, Simeone DM, Lubman DM. Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J Proteome Res 2012; 11(4): 2272-81.
[http://dx.doi.org/10.1021/pr201059g] [PMID: 22335271]
[106]
Lee SH, Kim H, Hwang JH, et al. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival. Pancreas 2014; 43(3): 380-8.
[http://dx.doi.org/10.1097/MPA.0000000000000097] [PMID: 24622067]
[107]
Salaria S, Means A, Revetta F, Idrees K, Liu E, Shi C. Expression of CD24, a stem cell marker, in pancreatic and small intestinal neuroendocrine tumors. Am J Clin Pathol 2015; 144(4): 642-8.
[http://dx.doi.org/10.1309/AJCPMZY5P9TWNJJV] [PMID: 26386086]
[108]
Pei X, Zhu J, Yang R, et al. CD90 and CD24 co-expression is associated with pancreatic intraepithelial neoplasias. PLoS One 2016; 11(6) e0158021
[http://dx.doi.org/10.1371/journal.pone.0158021] [PMID: 27332878]
[109]
Kitaura Y, Chikazawa N, Tasaka T, et al. Transforming growth factor β1 contributes to the invasiveness of pancreatic ductal adenocarcinoma cells through the regulation of CD24 expression. Pancreas 2011; 40(7): 1034-42.
[http://dx.doi.org/10.1097/MPA.0b013e31821ea286] [PMID: 21697762]
[110]
Arik D, Can C, Dündar E, Kabukçuoğlu S, Paşaoğlu Ö. Prognostic significance of CD24 in clear cell renal cell carcinoma. Pathol Oncol Res 2017; 23(2): 409-16.
[http://dx.doi.org/10.1007/s12253-016-0128-8] [PMID: 27738793]
[111]
Lee HJ, Kim DI, Kwak C, Ku JH, Moon KC. Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology 2008; 72(3): 603-7.
[http://dx.doi.org/10.1016/j.urology.2008.01.061] [PMID: 18384848]
[112]
Smith SC, Oxford G, Wu Z, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006; 66(4): 1917-22.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3855] [PMID: 16488989]
[113]
Overdevest JB, Knubel KH, Duex JE, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci USA 2012; 109(51): 3588-96.
[http://dx.doi.org/10.1073/pnas.1113960109] [PMID: 23012401]
[114]
Liu C, Zheng S, Shen H, et al. Clinical significance of CD24 as a predictor of bladder cancer recurrence. Oncol Lett 2013; 6(1): 96-100.
[http://dx.doi.org/10.3892/ol.2013.1357] [PMID: 23946784]
[115]
Choi Y-L, Lee S-H, Kwon G-Y, et al. Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder. Arch Pathol Lab Med 2007; 131(2): 275-81.
[PMID: 17284113]
[116]
Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res 2011; 71(11): 3802-11.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-0519] [PMID: 21482678]
[117]
Farid RM, Sammour SA-E, Shehab ElDin ZA, Salman MI, Omran TI. Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma. Cancer Manag Res 2019; 11: 4677-90.
[http://dx.doi.org/10.2147/CMAR.S198348] [PMID: 31213893]
[118]
Winkler A, Zigeuner R, Rehak P, Hutterer G, Chromecki T, Langner C. CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Int J Pathol 2007; 450(1): 59-64.
[http://dx.doi.org/10.1007/s00428-006-0316-0]
[119]
Kristiansen G, Pilarsky C, Pervan J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004; 58(2): 183-92.
[http://dx.doi.org/10.1002/pros.10324] [PMID: 14716744]
[120]
Kristiansen G, Pilarsky C, Wissmann C, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005; 205(3): 359-76.
[http://dx.doi.org/10.1002/path.1676] [PMID: 15532095]
[121]
Schostak M, Krause H, Miller K, et al. Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer. BMC Urol 2006; 6: 7.
[http://dx.doi.org/10.1186/1471-2490-6-7] [PMID: 16539730]
[122]
Nagy B, Szendroi A, Romics I. Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathol Oncol Res 2009; 15(2): 279-83.
[http://dx.doi.org/10.1007/s12253-008-9077-1] [PMID: 18752058]
[123]
Petkova N, Hennenlotter J, Sobiesiak M, et al. Surface CD24 distinguishes between low differentiated and transit-amplifying cells in the basal layer of human prostate. Prostate 2013; 73(14): 1576-90.
[http://dx.doi.org/10.1002/pros.22708] [PMID: 23836489]
[124]
Senner V, Sturm A, Baur I, Schrell UH, Distel L, Paulus W. CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol 1999; 58(8): 795-802.
[http://dx.doi.org/10.1097/00005072-199908000-00002] [PMID: 10446804]
[125]
Deng J, Gao G, Wang L, Wang T, Yu J, Zhao Z. CD24 expression as a marker for predicting clinical outcome in human gliomas. J Biomed Biotechnol 2012; 2012, 517172
[http://dx.doi.org/10.1155/2012/517172] [PMID: 22500096]
[126]
Sandén E, Dyberg C, Krona C, et al. Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas. J Neurooncol 2015; 123(1): 1-13.
[http://dx.doi.org/10.1007/s11060-015-1758-5] [PMID: 25820321]
[127]
Robson JP, Remke M, Kool M, et al. Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells. PLoS One 2019; 14(1)e0210665
[http://dx.doi.org/10.1371/journal.pone.0210665] [PMID: 30657775]
[128]
Wu X, Wang W, Lai X, et al. CD24 and PRAME are novel grading and prognostic indicators for pineal parenchymal tumors of intermediate differentiation. Am J Surg Pathol 2020; 44(1): 11-20.
[PMID: 31567202]
[129]
Li J, Li C, Yuan H, Gong F. Clinical value of CD24 expression in retinoblastoma. J Biomed Biotechnol 2012; 2012, 158084
[http://dx.doi.org/10.1155/2012/158084] [PMID: 22745528]
[130]
Shi Y, Gong HL, Zhou L, Tian J, Wang Y. CD24: a novel cancer biomarker in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2012; 74(2): 78-85.
[http://dx.doi.org/10.1159/000335584] [PMID: 22354323]
[131]
Tang J, Cai H, Lin L, Xie P, Zhong W, Tang M. Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma. Clin Transl Oncol 2013; 15(7): 541-7.
[http://dx.doi.org/10.1007/s12094-012-0961-5]
[132]
Han SA, Jang JH, Won KY, Lim SJ, Song JY. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma. Pathol Res Pract 2017; 213(8): 956-63.
[http://dx.doi.org/10.1016/j.prp.2017.05.002] [PMID: 28687160]
[133]
Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R, Deissler H. Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumour Biol 2002; 23(3): 139-45.
[http://dx.doi.org/10.1159/000064030] [PMID: 12218294]
[134]
Yeo MK, Lee YM, Seong IO, et al. Up-regulation of cytoplasmic CD24 expression is associated with malignant transformation but favorable prognosis of colorectal adenocarcinoma. Anticancer Res 2016; 36(12): 6593-8.
[http://dx.doi.org/10.21873/anticanres.11264] [PMID: 27919988]
[135]
Gilad N, Zukerman H, Pick M, Gatt ME. The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression. Oncotarget 2019; 10(52): 5480-91.
[http://dx.doi.org/10.18632/oncotarget.27190] [PMID: 31534632]
[136]
Cremers N, Neeb A, Uhle T, et al. CD24 is not required for tumor initiation and growth in murine breast and prostate cancer models. PLoS One 2016; 11(3) e0151468
[http://dx.doi.org/10.1371/journal.pone.0151468] [PMID: 26978528]
[137]
Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997; 89(9): 3385-95.
[http://dx.doi.org/10.1182/blood.V89.9.3385] [PMID: 9129046]
[138]
Aigner S, Ramos CL, Hafezi-Moghadam A, et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998; 12(12): 1241-51.
[http://dx.doi.org/10.1096/fasebj.12.12.1241] [PMID: 9737727]
[139]
Friederichs J, Zeller Y, Hafezi-Moghadam A, Gröne HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000; 60(23): 6714-22.
[PMID: 11118057]
[140]
Myung JH, Gajjar KA, Pearson RM, Launiere CA, Eddington DT, Hong S. Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin. Anal Chem 2011; 83(3): 1078-83.
[http://dx.doi.org/10.1021/ac102901e] [PMID: 21207944]
[141]
Kadmon G, Imhof BA, Altevogt P, Schachner M. Adhesive hierarchy involving the cell adhesion molecules L1, CD24, and alpha 6 integrin in murine neuroblastoma N2A cells. Biochem Biophys Res Commun 1995; 214(1): 94-101.
[http://dx.doi.org/10.1006/bbrc.1995.2261] [PMID: 7669058]
[142]
Sammar M, Aigner S, Altevogt P. Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta 1997; 1337(2): 287-94.
[http://dx.doi.org/10.1016/S0167-4838(96)00177-X] [PMID: 9048906]
[143]
Barash U, Spyrou A, Liu P, et al. Heparanase promotes glioma progression via enhancing CD24 expression. Int J Cancer 2019; 145(6): 1596-608.
[http://dx.doi.org/10.1002/ijc.32375] [PMID: 31032901]
[144]
Zimmerer RM, Ludwig N, Kampmann A, et al. CD24+ tumor-initiating cells from oral squamous cell carcinoma induce initial angiogenesis in vivo. Microvasc Res 2017; 112: 101-8.
[http://dx.doi.org/10.1016/j.mvr.2017.03.006] [PMID: 28344048]
[145]
Chan SH, Tsai KW, Chiu SY, et al. Identification of the novel role of CD24 as an oncogenesis regulator and therapeutic target for triple-negative breast cancer. Mol Cancer Ther 2019; 18(1): 147-61.
[http://dx.doi.org/10.1158/1535-7163.MCT-18-0292] [PMID: 30381446]
[146]
Wang X, Zhang Y, Zhao Y, et al. CD24 promoted cancer cell angiogenesis via Hsp90-mediated STAT3/VEGF signaling pathway in colorectal cancer. Oncotarget 2016; 7(34): 55663-76.
[http://dx.doi.org/10.18632/oncotarget.10971] [PMID: 27494878]
[147]
Deng W, Gu L, Li X, et al. CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells. J Transl Med 2016; 14: 32.
[http://dx.doi.org/10.1186/s12967-016-0787-y] [PMID: 26830684]
[148]
Sammar M, Gulbins E, Hilbert K, Lang F, Altevogt P. Mouse CD24 as a signaling molecule for integrin-mediated cell binding: functional and physical association with src-kinases. Biochem Biophys Res Commun 1997; 234(2): 330-4.
[http://dx.doi.org/10.1006/bbrc.1997.6639] [PMID: 9177270]
[149]
Baumann P, Thiele W, Cremers N, et al. CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci 2012; 69(3): 435-48.
[http://dx.doi.org/10.1007/s00018-011-0756-9] [PMID: 21710320]
[150]
Runz S, Mierke CT, Joumaa S, Behrens J, Fabry B, Altevogt P. CD24 induces localization of beta1 integrin to lipid raft domains. Biochem Biophys Res Commun 2008; 365(1): 35-41.
[http://dx.doi.org/10.1016/j.bbrc.2007.10.139] [PMID: 17980703]
[151]
Bretz NP, Salnikov AV, Perne C, et al. CD24 controls Src/STAT3 activity in human tumors. Cell Mol Life Sci 2012; 69(22): 3863-79.
[http://dx.doi.org/10.1007/s00018-012-1055-9] [PMID: 22760497]
[152]
Burgos-Ojeda D, Wu R, McLean K, et al. CD24+ ovarian cancer cells are enriched for cancer-initiating cells and dependent on jak2 signaling for growth and metastasis. Mol Cancer Ther 2015; 14(7): 1717-27.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0607] [PMID: 25969154]
[153]
Bretz N, Noske A, Keller S, et al. CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis 2012; 29(1): 27-38.
[http://dx.doi.org/10.1007/s10585-011-9426-4] [PMID: 21984372]
[154]
Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002; 62(24): 7328-34.
[PMID: 12499276]
[155]
Kang KS, Choi YP, Gao MQ, et al. CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype. Biochem Biophys Res Commun 2013; 432(2): 333-8.
[http://dx.doi.org/10.1016/j.bbrc.2013.01.102] [PMID: 23396061]
[156]
Leelawat K, Keeratichamroen S, Leelawat S, Tohtong R. CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2. Oncol Lett 2013; 6(5): 1439-46.
[http://dx.doi.org/10.3892/ol.2013.1587] [PMID: 24179538]
[157]
Schabath H, Runz S, Joumaa S, Altevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006; 119(Pt 2): 314-25.
[http://dx.doi.org/10.1242/jcs.02741] [PMID: 16390867]
[158]
Suyama K, Onishi H, Imaizumi A, et al. CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells. Cancer Lett 2016; 374(1): 44-53.
[http://dx.doi.org/10.1016/j.canlet.2015.12.013] [PMID: 26797459]
[159]
Naumov I, Zilberberg A, Shapira S, et al. CD24 knockout prevents colorectal cancer in chemically induced colon carcinogenesis and in APC(Min)/CD24 double knockout transgenic mice. Int J Cancer 2014; 135(5): 1048-59.
[http://dx.doi.org/10.1002/ijc.28762] [PMID: 24500912]
[160]
Thomas S, Harding MA, Smith SC, et al. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res 2012; 72(21): 5600-12.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3666] [PMID: 22926560]
[161]
Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA, Kamat AM. Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep 2017; 7(1): 9602.
[http://dx.doi.org/10.1038/s41598-017-08796-z] [PMID: 28851898]
[162]
Agarwal N, Dancik GM, Goodspeed A, et al. GON4L drives cancer growth through a YY1-androgen receptor-CD24 axis. Cancer Res 2016; 76(17): 5175-85.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-1099] [PMID: 27312530]
[163]
Kaipparettu BA, Malik S, Konduri SD, et al. Estrogen-mediated downregulation of CD24 in breast cancer cells. Int J Cancer 2008; 123(1): 66-72.
[http://dx.doi.org/10.1002/ijc.23480] [PMID: 18404683]
[164]
Zheng J, Li Y, Yang J, et al. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer 2011; 11(251): 251.
[http://dx.doi.org/10.1186/1471-2407-11-251] [PMID: 21676268]
[165]
Song SP, Zhang SB, Liu R, et al. NDRG2 down-regulation and CD24 up-regulation promote tumor aggravation and poor survival in patients with gallbladder carcinoma. Med Oncol 2012; 29(3): 1879-85.
[http://dx.doi.org/10.1007/s12032-011-0110-y] [PMID: 22135002]
[166]
Wang H, Wang W, Wang X, et al. Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma. Med Oncol 2012; 29(5): 3162-8.
[http://dx.doi.org/10.1007/s12032-012-0231-y] [PMID: 22528516]
[167]
Li B, Shao Q, Ji D, Li F, Guo X, Chen G. Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma. Diagn Pathol 2014; 9: 209.
[http://dx.doi.org/10.1186/s13000-014-0209-5] [PMID: 25338637]
[168]
Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995; 55(20): 4717-21.
[PMID: 7553654]
[169]
Wang L, Liu R, Ye P, et al. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation. Nat Commun 2015; 6: 5909.
[http://dx.doi.org/10.1038/ncomms6909] [PMID: 25600590]
[170]
Zhang W, Yi B, Wang C, et al. Silencing of CD24 Enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells. Clin Cancer Res 2016; 22(10): 2545-54.
[171]
Weng C-C, Ding P-Y, Liu Y-H, et al. Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis. Oncogene 2019; 38(12): 2005-19.
[http://dx.doi.org/10.1038/s41388-018-0575-7] [PMID: 30467381]
[172]
Li W, Zhang W, Luo J, et al. Alpha1,3 fucosyltransferase VII plays a role in colorectal carcinoma metastases by promoting the carbohydration of glycoprotein CD24. Oncol Rep 2010; 23(6): 1609-17.
[PMID: 20428816]
[173]
Chen Y-C, Lee T-H, Tzeng S-L. Reduced DAXX expression is associated with reduced cd24 expression in colorectal cancer. Cells 2019; 8(10) E1242
[http://dx.doi.org/10.3390/cells8101242] [PMID: 31614769]
[174]
Li L, Chen J, Ge C, et al. CD24 isoform a promotes cell proliferation, migration and invasion and is downregulated by EGR1 in hepatocellular carcinoma. OncoTargets Ther 2019; 12: 1705-16.
[http://dx.doi.org/10.2147/OTT.S196506] [PMID: 30881025]
[175]
Taniuchi K, Nishimori I, Hollingsworth MA. Intracellular CD24 inhibits cell invasion by post-transcriptional regulation of BART through interaction with G3BP. Cancer Res 2011; 71(3): 895-905.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-2743] [PMID: 21266361]
[176]
Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells. Cancer Sci 2014; 105(7): 779-87.
[http://dx.doi.org/10.1111/cas.12427] [PMID: 24754246]
[177]
Deng X, Apple S, Zhao H, et al. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget 2017; 8(24): 38294-308.
[http://dx.doi.org/10.18632/oncotarget.16203] [PMID: 28418843]
[178]
Hüser L, Sachindra S, Granados K, et al. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. Int J Cancer 2018; 143(12): 3131-42.
[http://dx.doi.org/10.1002/ijc.31609] [PMID: 29905375]
[179]
Lu S, Yao Y, Xu G, et al. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis 2018; 9(6): 646.
[http://dx.doi.org/10.1038/s41419-018-0681-z] [PMID: 29844385]
[180]
Guo-Yun C, Jie T, Pan Z, Yang L. CD24 and siglec-10 selectively repress tissue damage–induced immune responses. Science 2009; 323(5922): 1722-5.
[http://dx.doi.org/10.1126/science.1168988] [PMID: 19264983]
[181]
Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 2019; 572(7769): 392-6.
[http://dx.doi.org/10.1038/s41586-019-1456-0] [PMID: 31367043]
[182]
Wan X, Cheng C, Shao Q, Lin Z, Lu S, Chen Y. CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment. Tumour Biol 2016; 37(5): 6073-84.
[http://dx.doi.org/10.1007/s13277-015-4442-7] [PMID: 26608371]
[183]
Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY) 2016; 8(4): 603-19.
[http://dx.doi.org/10.18632/aging.100934] [PMID: 27019364]
[184]
Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124(3): 511-5.
[http://dx.doi.org/10.1002/ijc.24064] [PMID: 19003982]
[185]
Li YH, Sun X, Wang HB. Role of CD24 in anoikis resistance of ovarian cancer cells. J Technol Med Sci 2015; 35(3): 390-6.
[http://dx.doi.org/10.1007/s11596-015-1443-0]
[186]
Lee KM, Ju JH, Jang K, et al. CD24 regulates cell proliferation and transforming growth factor β-induced epithelial to mesenchymal transition through modulation of integrin β1 stability. Cell Signal 2012; 24(11): 2132-42.
[http://dx.doi.org/10.1016/j.cellsig.2012.07.005] [PMID: 22800863]
[187]
Lubeseder-Martellato C, Hidalgo-Sastre A, Hartmann C, et al. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Oncotarget 2016; 7(31): 49156-68.
[http://dx.doi.org/10.18632/oncotarget.9402] [PMID: 27203385]
[188]
Vlashi E, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol 2015; 31: 28-35.
[http://dx.doi.org/10.1016/j.semcancer.2014.07.001] [PMID: 25025713]
[189]
Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010; 29(18): 2672-80.
[http://dx.doi.org/10.1038/onc.2010.35] [PMID: 20190812]
[190]
Koh J, Lee SB, Park H, Lee HJ, Cho NH, Kim J. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells. Biochem Biophys Res Commun 2012; 427(2): 373-8.
[http://dx.doi.org/10.1016/j.bbrc.2012.09.067] [PMID: 22995296]
[191]
Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9(1): 50-63.
[http://dx.doi.org/10.1016/j.stem.2011.06.005] [PMID: 21726833]
[192]
Li Y, Wang R, Xiong S, et al. Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling. J Mol Med (Berl) 2019; 97(2): 243-55.
[http://dx.doi.org/10.1007/s00109-018-1731-9] [PMID: 30564864]
[193]
Ke J, Wu X, Wu X, et al. A subpopulation of CD24+ cells in colon cancer cell lines possess stem cell characteristics. Neoplasma 2012; 59(3): 282-8.
[http://dx.doi.org/10.4149/neo_2012_036] [PMID: 22329848]
[194]
Okano M, Konno M, Kano Y, et al. Human colorectal CD24+ cancer stem cells are susceptible to epithelial-mesenchymal transition. Int J Oncol 2014; 45(2): 575-80.
[http://dx.doi.org/10.3892/ijo.2014.2462] [PMID: 24858473]
[195]
Yang CH, Wang HL, Lin YS, et al. Identification of CD24 as a cancer stem cell marker in human nasopharyngeal carcinoma. PLoS One 2014; 9(6) e99412
[http://dx.doi.org/10.1371/journal.pone.0099412] [PMID: 24955581]
[196]
Ooki A, VandenBussche CJ, Kates M, et al. CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. Br J Cancer 2018; 119(8): 961-70.
[http://dx.doi.org/10.1038/s41416-018-0291-7] [PMID: 30327565]
[197]
Tang M-R, Guo J-Y, Wang D, Xu N. Identification of CD24 as a marker for tumorigenesis of melanoma. OncoTargets Ther 2018; 11: 3401-6.
[http://dx.doi.org/10.2147/OTT.S157043] [PMID: 29928131]
[198]
Zhang C, Li C, He F, Cai Y, Yang H. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol 2011; 137(11): 1679-86.
[http://dx.doi.org/10.1007/s00432-011-1038-5] [PMID: 21882047]
[199]
Shen YA, Wang CY, Chuang HY, et al. CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation. Oncotarget 2016; 7(36): 58351-66.
[http://dx.doi.org/10.18632/oncotarget.11113] [PMID: 27521216]
[200]
Ortiz-Montero P, Liu-Bordes W-Y, Londoño-Vallejo A, Vernot J-P. CD24 expression and stem-associated features define tumor cell heterogeneity and tumorigenic capacities in a model of carcinogenesis. Cancer Manag Res 2018; 10: 5767-84.
[http://dx.doi.org/10.2147/CMAR.S176654] [PMID: 30510447]
[201]
Liu H, Wang YJ, Bian L, Fang ZH, Zhang QY, Cheng JX. CD44+/CD24+ cervical cancer cells resist radiotherapy and exhibit properties of cancer stem cells. Eur Rev Med Pharmacol Sci 2016; 20(9): 1745-54.
[PMID: 27212166]
[202]
Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67(3): 1030-7.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-2030] [PMID: 17283135]
[203]
Yang XF, Ma G, Feng NH, Yu DS, Wu Y, Li C. Twist2 and CD24 expression alters renal microenvironment in obesity associated kidney cancer. Eur Rev Med Pharmacol Sci 2018; 22(2): 358-64.
[PMID: 29424894]
[204]
Liu AY, Cai Y, Mao Y, et al. Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis 2014; 35(3): 537-45.
[http://dx.doi.org/10.1093/carcin/bgt364] [PMID: 24193512]
[205]
Roudi R, Madjd Z, Ebrahimi M, Samani FS, Samadikuchaksaraei A. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Cell Mol Biol Lett 2014; 19(1): 23-36.
[http://dx.doi.org/10.2478/s11658-013-0112-1] [PMID: 24363164]
[206]
Sagiv E, Kazanov D, Arber N. CD24 plays an important role in the carcinogenesis process of the pancreas. Biomed Pharmacother 2006; 60(6): 280-4.
[http://dx.doi.org/10.1016/j.biopha.2006.06.006]
[207]
Sagiv E, Starr A, Rozovski U, et al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008; 68(8): 2803-12.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-6463] [PMID: 18413748]
[208]
Salnikov AV, Bretz NP, Perne C, et al. Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br J Cancer 2013; 108(7): 1449-59.
[http://dx.doi.org/10.1038/bjc.2013.102] [PMID: 23511563]
[209]
Kim JB, Ko E, Han W, et al. CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer 2008; 8: 118.
[http://dx.doi.org/10.1186/1471-2407-8-118] [PMID: 18433506]
[210]
He H, Tu X, Zhang J, et al. A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging. Immunobiology 2015; 220(12): 1328-36.
[http://dx.doi.org/10.1016/j.imbio.2015.07.010] [PMID: 26255089]
[211]
Zangemeister-Wittke U, Lehmann HP, Waibel R, Wawrzynczak EJ, Stahel RA. Action of a CD24-specific deglycosylated ricin-A-chain immunotoxin in conventional and novel models of small-cell-lung-cancer xenograft. Int J Cancer 1993; 53(3): 521-8.
[http://dx.doi.org/10.1002/ijc.2910530327] [PMID: 8381397]
[212]
Schnell R, Katouzi AA, Linnartz C, et al. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt’s lymphoma model in SCID mice. Int J Cancer 1996; 66(4): 526-31.
[http://dx.doi.org/10.1002/(SICI)10970215(19960516)66:4<526:AID-IJC17>3.0.CO;2-5] [PMID: 8635869]
[213]
Shapira S, Shapira A, Starr A, et al. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology 2011; 140(3): 935-46.
[http://dx.doi.org/10.1053/j.gastro.2010.12.004] [PMID: 21147107]
[214]
Bharali DJ, Sudha T, Cui H, Mian BM, Mousa SA. Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine (Lond) 2017; 13(1): 263-73.
[http://dx.doi.org/10.1016/j.nano.2016.08.017] [PMID: 27565690]
[215]
Ma Z, He H, Sun F, et al. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo. J Cancer Res Clin Oncol 2017; 143(10): 1929-40.
[http://dx.doi.org/10.1007/s00432-017-2436-0] [PMID: 28536738]
[216]
Sun F, Wang T, Jiang J, et al. Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design. Oncotarget 2017; 8(31): 51238-52.
[http://dx.doi.org/10.18632/oncotarget.17228] [PMID: 28881644]
[217]
Sun F, Wang Y, Luo X, et al. Anti-CD24 antibody-nitric oxide conjugate selectively and potently suppresses hepatic carcinoma. Cancer Res 2019; 79(13): 3395-405.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-2839] [PMID: 30918001]
[218]
Wang T, Sun F, Xie W, et al. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Cancer Lett 2016; 372(2): 166-78.
[http://dx.doi.org/10.1016/j.canlet.2016.01.001] [PMID: 26791237]
[219]
Han Y, Sun F, Zhang X, et al. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy. J Cancer Res Clin Oncol 2019; 145(5): 1179-90.
[http://dx.doi.org/10.1007/s00432-019-02865-8] [PMID: 30778749]
[220]
Su D, Deng H, Zhao X, et al. Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy 2009; 11(5): 642-52.
[http://dx.doi.org/10.1080/14653240902878308] [PMID: 19593703]
[221]
Okabe H, Aoki K, Yogosawa S, Saito M, Marumo K, Yoshida K. Downregulation of CD24 suppresses bone metastasis of lung cancer. Cancer Sci 2018; 109(1): 112-20.
[http://dx.doi.org/10.1111/cas.13435] [PMID: 29095550]
[222]
Jiao XL, Zhao C, Niu M, Chen D. Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells. Eur Rev Med Pharmacol Sci 2013; 17(13): 1709-15.
[PMID: 23852892]
[223]
Ma ZL, Chen YP, Song JL, Wang YQ. Knockdown of CD24 inhibits proliferation, invasion and sensitizes breast cancer MCF-7 cells to tamoxifen in vitro. Eur Rev Med Pharmacol Sci 2015; 19(13): 2394-9.
[PMID: 26214774]
[224]
Kinghorn AB, Fraser LA, Lang S, Shiu SCC, Tanner JA. Aptamer bioinformatics. Int J Mol Sci 2017; 18(12) E2516
[http://dx.doi.org/10.3390/ijms18122516] [PMID: 29186809]
[225]
Fafińska J, Czech A, Sitz T, Ignatova Z, Hahn U. DNA aptamers for the malignant transformation marker CD24. Nucleic Acid Ther 2018; 28(6): 326-34.
[http://dx.doi.org/10.1089/nat.2018.0748] [PMID: 30407110]
[226]
Zhuo J, Wang X. Combination of targeting CD24 and inhibiting autophagy suppresses the proliferation and enhances the apoptosis of colorectal cancer cells. Mol Med Rep 2019; 20(1): 539-48.
[http://dx.doi.org/10.3892/mmr.2019.10288] [PMID: 31180548]
[227]
Maliar A, Servais C, Waks T, et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012; 143(5): 1375-1384.e5.
[http://dx.doi.org/10.1053/j.gastro.2012.07.017] [PMID: 22819865]
[228]
Klapdor R, Wang S, Morgan M, et al. Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer. Int J Mol Sci 2019; 20(3) E660
[http://dx.doi.org/10.3390/ijms20030660] [PMID: 30717444]
[229]
Yang Y, Hou J, Lin Z, et al. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol 2014; 11(2): 184-96.
[http://dx.doi.org/10.1038/cmi.2013.64] [PMID: 24488178]
[230]
Toubai T, Rossi C, Oravecz-Wilson K, et al. Siglec-G represses DAMP-mediated effects on T cells. JCI Insight 2017; 2(14): 92293.
[http://dx.doi.org/10.1172/jci.insight.92293] [PMID: 28724800]
[231]
Tian RR, Zhang MX, Zhang LT, et al. CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS. Antiviral Res 2018; 157: 9-17.
[http://dx.doi.org/10.1016/j.antiviral.2018.07.004] [PMID: 29983395]
[232]
Toubai T, Hou G, Mathewson N, et al. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood 2014; 123(22): 3512-23.
[http://dx.doi.org/10.1182/blood-2013-12-545335] [PMID: 24695850]
[233]
Zheng X, Wu W, Liu Y, Zheng P. Methods of use of soluble CD24 for therapy of rheumatoid arthritis Patents 2014 Available at: https://patents.google.com/patent/US8808697B2/en

Rights & Permissions Print Cite
Article Metrics
126
12
© 2024 Bentham Science Publishers | Privacy Policy